In this review, we systematically elaborate on the targeting of SIRT6 to regulate glucose and lipid metabolism to delay DN progression and on the feasibility of utilizing SIRT6 in DN treatment. The gene discussed is SIRT6; the disease is liver dysplastic nodule.